NCT04396366View on ClinicalTrials.gov

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

PHASE2TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 2, 2021

Primary Completion Date

June 15, 2023

Study Completion Date

June 21, 2023

Conditions
Bronchiectasis
Interventions
DRUG

QBW251

QBW251, 300 mg, oral use, one capsule, twice daily.

DRUG

Placebo

Matching placebo, 300 mg, oral use, one capsule, twice daily.

Trial Locations (14)

17007

Novartis Investigative Site, Girona

30625

Novartis Investigative Site, Hanover

55128

Novartis Investigative Site, Mainz

60596

Novartis Investigative Site, Frankfurt

200433

Novartis Investigative Site, Shanghai

510120

Novartis Investigative Site, Guangzhou

08035

Novartis Investigative Site, Barcelona

LS9 7TF

Novartis Investigative Site, Leeds

CB2 0AY

Novartis Investigative Site, Cambridge

EH10 5HF

Novartis Investigative Site, Edinburgh

L7 8XP

Novartis Investigative Site, Liverpool

L9 7AL

Novartis Investigative Site, Liverpool

SW3 6PH

Novartis Investigative Site, London

M23 9LT

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
collaborator

Innovative Medicines Initiative

OTHER

lead

Novartis Pharmaceuticals

INDUSTRY